This content is from: Patents

Myriad settles BRCA litigation following Federal Circuit ruling

Myriad Genetics has settled litigation with three of the laboratories it accused of infringing patents on two genes associated with breast and ovarian cancer, following a Federal Circuit ruling last month confirming some of its claims were patent ineligible

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an Managing IP subscriber? Login here


Instant access to all of our content. Membership Options | 30 Day Trial